TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31

Tyra Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$19.34+0.82 (+4.43%)

Close on Oct 19, 2026

Market cap: $1.28B
P/E (TTM): –
Dividend yield: –

Tyra Biosciences, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	77	93	59	252	302	15	0.11
Cash & Short-Term Investments	77	93	59	252	302	15	0.11
Prepaid Expenses & Other	9.45	6.02	8.20	6.08	1.88	0.06	–
Total Current Assets	265	347	212	257	304	15	–
Property, Plant & Equipment	1.31	1.65	1.63	1.08	1.03	0.30	–
Gross Property, Plant & Equipment	–	2.93	2.44	1.54	1.20	0.34	–
Accumulated Depreciation	–	-1.28	-0.81	-0.46	-0.17	-0.04	–
Operating Lease Right-of-Use Assets	5.57	–	–	–	–	0.15	–
Other Long-Term Assets	9.27	7.38	5.03	4.35	0.31	0.02	–
Total Assets	283	364	226	266	307	16	–
Accounts Payable	1.18	0.59	4.66	1.15	0.60	0.66	–
Current Portion of Leases	0.47	0.41	0.28	0.14	0.20	0.14	–
Total Current Liabilities	18	15	15	5.70	3.62	1.86	–
Long-Term Leases	5.34	5.81	6.22	2.48	0.98	0	–
Operating Lease Liabilities	5.81	6.22	6.50	2.62	1.18	0.14	–
Other Long-Term Liabilities	0	0.00	0.05	0.17	0.37	0.14	–
Total Liabilities	23	20	22	8.35	4.96	2.00	–
Preferred Stock	0	0	0	0	0	0	–
Common Stock	0.01	0.01	0.00	0.00	0.00	0	–
Additional Paid-In Capital	630	594	369	354	342	0.44	–
Retained Earnings	-371	-251	-165	-96	-40	-14	–
Comprehensive Income & Other	0.39	0.77	0.38	0	–	–	–
Shareholders' Equity	259	343	204	258	302	-14	-4.74
Total Equity	259	343	204	258	302	-14	-4.74
Total Liabilities & Equity	283	364	226	266	307	16	–
Shares Outstanding(shares)	54	51	43	42	41	1.83	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -39.8%

Financial strength

Current ratio: 14.91
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 299.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.61
Dividend yield: –